12:54

AI x Bio Pitch Contest — Eigen Bio

Kristin Gleitsman explains how Eigen Bio uses patient samples and an RNA foundation model to explore therapeutic targets.

Xin

Chapters

  1. 00:00 The gap between models and human disease
  2. 02:06 Patient samples and the Eigen-1 model
  3. 02:47 Early analyses and clinical signals
  4. 03:57 Therapeutic programs and feedback
  5. 06:53 Q&A: Development pace and revenue
  6. 09:14 Q&A: Target discovery and repurposing
  7. 11:04 Q&A: Precision therapeutics and indications
Summary

Eigen Bio Chief Science Officer Kristin Gleitsman describes a model-guided approach to finding biological targets and building therapeutic programs from patient-response evidence. She discusses the company's Eigen-1 RNA model, early analyses, and the proposed feedback cycle between experiments, clinical data, and new predictions. Judges ask about development pace, revenue models, target discovery, and precision therapeutics.

Watch next

More from the studio

TechCrunch Disrupt 2026 · AIEEV3:12Open Mic

TechCrunch Disrupt 2026 · AIEEV

AIEEV co-founder Hyeonkyeong (Karen) Kim explains the approach behind Air Cloud: connecting edge GPU devices for AI inference, supporting container-based deployment and autoscaling, and addressing hardware and network security. Recorded at TechCrunch Disrupt 2026.

Oct 22, 2026
AI x Bio Pitch Contest1:10

AI x Bio Pitch Contest

A short look at the September 29 AI x Bio Pitch Contest in San Francisco, from company pitches to the award presentations.

Oct 5, 2026
AI x Bio Pitch Contest — Optagon Labs9:25

AI x Bio Pitch Contest — Optagon Labs

Khalil Kaddoura presents Optagon Labs' proposed AI-driven loop for drug optimization and lab testing.

Oct 5, 2026